Moderna, Inc. has disclosed an update regarding its beneficial ownership in a recent filing with the SEC. The filing reveals that FMR LLC, a prominent investment management firm, now holds 14.8% of Moderna's common stock. This significant stake underscores the continued interest of institutional investors in the biotechnology sector, particularly as the industry evolves in the post-pandemic landscape.
Background
Moderna, Inc. is a biotechnology company specializing in the development of biological products, specifically in the area of mRNA technology. The company is listed on the Nasdaq under the ticker symbol MRNA and is classified under the SIC code 2836, which pertains to Biological Products (No Diagnostic Substances). Recent filings include a Schedule 13G/A submitted on November 5, 2026, which provides updates on ownership stakes.
What the Filing Says
The recent Schedule 13G/A filing indicates that FMR LLC beneficially owns approximately 58,929,948 shares of Moderna, equating to 14.8% of the company’s common stock. The filing also notes that Abigail P. Johnson, a key figure at FMR LLC, is among the reporting persons.
Impact
This update may affect various stakeholders, including investors and analysts monitoring Moderna's performance and strategic direction. The substantial ownership by FMR LLC could signal confidence in Moderna's future growth potential, especially as the company continues to innovate within the biological products sector.
What's Next
The filing does not say what happens next.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





